Oct 29, 2024
Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA(R) (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting
Aug 28, 2024
Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary
Aug 12, 2024
Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program
May 21, 2024
ZYMFENTRA(TM) (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
May 17, 2024
Celltrion USA announces two-year data for ZYMFENTRA(TM)(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference
May 09, 2024
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost
Apr 28, 2024
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRA(TM)
Mar 10, 2024
Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)
Jan 28, 2024
Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab)